Results 221 to 230 of about 11,341 (256)
Some of the next articles are maybe not open access.
PROTACs in Treatment of Cancer: A Review
Mini-Reviews in Medicinal Chemistry, 2021Cancer treatment has become a major challenge amidst the resistance and relapse caused by the various treatments available. The PROteolysis TAargeting Chimera (PROTAC) technology involves the degradation of target protein against the inhibition by small drug molecules. The PROTACs with high potency and activity have been frequently reported; however,
Poonam Arora +4 more
openaire +2 more sources
Optimization of a Series of RIPK2 PROTACs
Journal of Medicinal Chemistry, 2021Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of the inhibitor of apoptosis (IAP) family of E3 ligases.
Afjal H. Miah +17 more
openaire +2 more sources
Nature Chemical Biology
Targeted protein degradation has emerged as a promising approach in drug discovery, harnessing a cell's intrinsic machinery to eliminate disease-related proteins. Now, a study paves the way to translating this technology into potential anti-mycobacterial therapies, by exploiting the bacterial protein-degradation complex.
Preti, Delia +2 more
openaire +3 more sources
Targeted protein degradation has emerged as a promising approach in drug discovery, harnessing a cell's intrinsic machinery to eliminate disease-related proteins. Now, a study paves the way to translating this technology into potential anti-mycobacterial therapies, by exploiting the bacterial protein-degradation complex.
Preti, Delia +2 more
openaire +3 more sources
Bioorganic & Medicinal Chemistry, 2023
RNA-binding proteins (RBPs) dysfunction has been implicated in a number of diseases, and RBPs have traditionally been considered to be undruggable targets. Here, targeted degradation of RBPs is achieved based on the aptamer-based RNA-PROTAC, which consists of a genetically encoded RNA scaffold and a synthetic heterobifunctional molecule.
Yan Xu +12 more
openaire +2 more sources
RNA-binding proteins (RBPs) dysfunction has been implicated in a number of diseases, and RBPs have traditionally been considered to be undruggable targets. Here, targeted degradation of RBPs is achieved based on the aptamer-based RNA-PROTAC, which consists of a genetically encoded RNA scaffold and a synthetic heterobifunctional molecule.
Yan Xu +12 more
openaire +2 more sources
PROTAC antibiotics: the time is now
Expert Opinion on Drug Discovery, 2023Novel antibiotics are needed to keep antibiotic resistance at bay and to improve treatment of the many drug-susceptible infections for which current therapies achieve poor cure rates. While revolutionizing human therapeutics, the concept of targeted protein degradation (TPD) by bifunctional proteolysis targeting chimeras (PROTACs) has not yet been ...
Jickky Palmae Sarathy +3 more
openaire +2 more sources
Targeted Degradation of Proteins by PROTACs
Current Protocols in Chemical Biology, 2010AbstractIn recent years, small interference RNAs (siRNAs) have greatly enhanced our understanding of protein functions by allowing knockdown of targeted proteins at the mRNA level. Similarly, in an effort to achieve degradation of targeted proteins at the post‐translational level, chimeric small molecules called “PROTACs” (PROteolysis TArgeting ...
Eun Ryoung, Jang +2 more
openaire +2 more sources
Bifunctional Molecules beyond PROTACs
Journal of Medicinal Chemistry, 2020Heterobifunctional molecules, which recruit E3 ligases to ubiquitinate a target protein of interest, have found wide application as both biological tools and molecules with the potential to have clinical effects. In their recent paper, Yamazoe et al. report a heterobifunctional molecule that recruits the phosphatase PP1 to promote the dephosphorylation
openaire +2 more sources
Targeted protein degradation by PROTACs
Pharmacology & Therapeutics, 2017Targeted protein degradation using the PROTAC technology is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein. PROTAC molecules are bifunctional small molecules that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degradation of the ...
Taavi K, Neklesa +2 more
openaire +2 more sources